TMS Co., Ltd. (TSE: 4891) (the "Company"), a clinical-stage biopharmaceutical company focused on discovering and accelerating the development of transformative medicines in areas of high unmet medical need, is pleased to announce that our strategic partner, Corxel Pharmaceuticals Limited (“CORXEL”), announced on January 22, 2026 (U.S. Eastern Time) that it has completed a US$287 million Series D-1 financing round.
The Company has acquired US$5 million equivalent common shares of CORXEL (at then‑current market value) on January 11, 2024 at no cost, (Notice of Strategic Alliance between TMS and JIXING) , and continues to hold these shares. The Company also received US$2.25 million (¥344 million) in dividends from CORXEL on February 6, 2025.
For further details regarding CORXEL’s financing, please refer to its official announcement:CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist
TMS Co., Ltd.
TMS Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative medicines for the treatment of serious diseases in areas of high unmet medical need. The Company’s pipeline consists of a family of small molecule compounds called SMTPs (Stachybotrys microspora triprenyl phenols) derived from a fungus. TMS’ lead program, TMS-007 (JX10), has demonstrated efficacy and safety in its Phase 2a study for the treatment of acute ischemic stroke. The Company’s robust pipeline also includes programs in resistant or uncontrolled hypertension, acute kidney injury, and spinal cord injury. TMS continues to explore new pipeline products by leveraging its established partnerships with leading academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit https://www.tms-japan.co.jp/. Investor and Media Contact:
End
